Global TAR DNA-Binding Protein 43 (TDP-43) Pipeline Report 2016 - Review of 5 Companies/Institutions & 7 Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016" report to their offering.

TAR DNA-Binding Protein 43 (TDP-43) pipeline target constitutes close to 7 molecules, out of which approximately 7 molecules are developed by companies. The report "TAR DNA-Binding Protein 43 - Pipeline Review, H1 2016" outlays comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

TAR DNA-Binding Protein 43 (TDP-43) TAR DNA-binding protein 43 or TDP-43 is a protein encoded by the TARDBP gene. It is involved in the regulation of CFTR splicing, microRNA biogenesis, apoptosis and cell division. It represses HIV-1 transcription by binding to the HIV-1 long terminal repeat. It stabilizes the low molecular weight neurofilament mRNA through a direct interaction with the 3' UTR. The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 3 respectively.

Furthermore, this report also reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

1. Introduction
2. TAR DNA-Binding Protein 43 Overview
3. Therapeutics Development
4. Pipeline Products for TAR DNA-Binding Protein 43 - Overview
5. Pipeline Products for TAR DNA-Binding Protein 43 - Comparative Analysis
6. TAR DNA-Binding Protein 43 - Therapeutics under Development by Companies
7. TAR DNA-Binding Protein 43 - Therapeutics under Investigation by Universities/Institutes
8. TAR DNA-Binding Protein 43 Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. TAR DNA-Binding Protein 43 - Products under Development by Companies
13. TAR DNA-Binding Protein 43 - Products under Investigation by Universities/Institutes
14. TAR DNA-Binding Protein 43 - Companies Involved in Therapeutics Development

• Biogen, Inc.
• ImStar Therapeutics Inc.
• Primary Peptides, Inc.
• SK Biopharmaceuticals Co., Ltd.
• TauRx Therapeutics Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/ldvbhm/tar_dnabinding

Related Topics: Central Nervous System Drugs